Last update: March 26, 2020

Lopinavir

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

Antivírico inhibidor de la proteasa del VIH. Utilizado, asociado a Ritonavir, en el tratamento del VIH/SiDA.
Se ha empleado de modo experimental en el tratamiento del coronavirus COVID-19 (Li 2020, Lim 2020, SEFH 2020).

Administración oral en dos dosis al día.

Sus datos farmacocinéticos (peso molecular moderadamente elevado y muy alto porcentaje de fijación a proteínas) explican el ínfimo paso a leche observado (Oumar 2018, Corbett 2014, Shapiro 2013, Palombi 2012).
Los niveles en plasma de lactantes cuyas madres lo tomaban fueron indetectables (Oumar 2018, Corbett 2014, Gandhi 2013, Shapiro 2013) o muy bajos (Gandhi 2013, Shapiro 2013, Palombi 2012).

Según la política adoptada por las autoridades sanitarias de cada país, la lactancia materna en madres con VIH / SIDA está o no aconsejada. Con el tratamiento antirretroviral de gran actividad (TARGA) la carga viral para VIH se puede reducir a cero, reduciendo el riesgo de transmisión de VIH a través de la lactancia materna a niveles semejantes a los de la alimentación con fórmula artificial.


See below the information of these related products:

Alternatives

We do not have alternatives for Lopinavir since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Group

Lopinavir belongs to this group or family:

Tradenames

Main tradenames from several countries containing Lopinavir in its composition:

  • Aluvia™. Contains other elements than Lopinavir in its composition
  • Aluvia (Алувиа)™. Contains other elements than Lopinavir in its composition
  • Aluvia (克力芝)™. Contains other elements than Lopinavir in its composition
  • Emletra ™. Contains other elements than Lopinavir in its composition
  • Kaletra™. Contains other elements than Lopinavir in its composition
  • Kaletra (Калетра)™. Contains other elements than Lopinavir in its composition
  • Kalmeltrex ™. Contains other elements than Lopinavir in its composition
  • Lopimune ™. Contains other elements than Lopinavir in its composition
  • Rilopravir™. Contains other elements than Lopinavir in its composition
  • Ritomax-L™. Contains other elements than Lopinavir in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 25 %
Molecular weight 629 daltons
Protein Binding 98 - 99 %
VD 0,9 - 1,8 l/Kg
pKa 13,39 -
Tmax 4,4 hours
T1/2 5 - 6 hours
M/P ratio 0,2 - 0,4 -
Theoretical Dose 0,1 - 0,28 mg/Kg/d
Relative Dose 0,23 - 2,1 %

References

  1. Li H, Wang YM, Xu JY, Cao B. [Potential antiviral therapeutics for 2019 Novel Coronavirus]. Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 5;43(0):E002. Abstract
  2. Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, Choe KW, Kang YM, Lee B, Park SJ. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci. 2020 Feb 17;35(6):e79. Abstract
  3. SEFH - Sociedad Española de Farmacia Hospitalaria. Procedimientos de farmacia hospitalaria para la gestión del tratamiento con antivirales en la enfermedad por el nuevo coronavirus sars-cov-2 (COVID-19). Recomendaciones de la Sociedad Española de Farmacia Hospitalaria. 2020 Full text (in our servers)
  4. Oumar AA, Bagayoko-Maiga K, Bahachimi A, Maiga M, Cere MC, Diarra Z, Chatelut E, Sylla M, Murphy RL, Dao S, Gandia P. Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali. J Pharmacol Exp Ther. 2018 Sep;366(3):479-484. Abstract
  5. Corbett AH, Kayira D, White NR, Davis NL, Kourtis AP, Chasela C, Martinson F, Phiri G, Musisi B, Kamwendo D, Hudgens MG, Hosseinipour MC, Nelson JA, Ellington SR, Jamieson DJ, van der Horst C, Kashuba A; BAN Study Team.. Antiretroviral pharmacokinetics in mothers and breastfeeding infants from 6 to 24 weeks post-partum: results of the BAN Study. Antivir Ther. 2014;19(6):587-95. Abstract
  6. Shapiro RL, Rossi S, Ogwu A, Moss M, Leidner J, Moffat C, Lockman S, Moyo S, Makhema J, Essex M, Capparelli E. Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Antivir Ther. 2013;18(4):585-90. Abstract
  7. Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D; Prevention of Malaria and HIV disease in Tororo (PROMOTE) study.. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):578-84. Abstract
  8. Palombi L, Pirillo MF, Andreotti M, Liotta G, Erba F, Sagno JB, Maulidi M, Ceffa S, Jere H, Marchei E, Pichini S, Galluzzo CM, Marazzi MC, Vella S, Giuliano M. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther. 2012;17(8):1511-9. Abstract

Total visits

1,198

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM